Soligenix Gains European Orphan Drug Designation for Behçet's Disease Therapy SGX945

The European Commission has granted orphan drug designation to Soligenix's investigational therapy SGX945 for the treatment of Behçet's disease, providing significant regulatory validation and development incentives for the rare disease treatment. This designation from a major global regulatory authority underscores the therapy's potential importance for patients with this serious condition while strengthening Soligenix's clinical pipeline.

Orphan drug designation in the European Union is specifically intended to encourage the development of treatments for rare diseases, which are defined as conditions affecting fewer than 5 in 10,000 people. For biotechnology companies like Soligenix, such designations from established global organizations carry meaningful implications, including potential market exclusivity, regulatory fee reductions, and protocol assistance during development. The recognition serves as a powerful validation of a therapy's potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent.

SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators. The therapy represents a novel approach to treating Behçet's disease, a chronic inflammatory disorder that can affect multiple body systems and for which treatment options remain limited. The orphan designation follows the company's broader development strategy for its pipeline of rare disease therapies.

The latest news and updates relating to Soligenix are available in the company's newsroom at https://ibn.fm/SNGX. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer.